Sertoli Cell Tumors of the Testes: Systematic Literature Review and Meta-Analysis of Outcomes in 435 Patients.
Josias GroggKym SchneiderPeter Karl BodeBenedikt KranzbühlerDaniel EberliTullio SulserAnja LorchJoerg BeyerThomas HermannsChristian Daniel FankhauserPublished in: The oncologist (2020)
Testicular Sertoli cell tumors usually present without metastatic disease and show low local recurrence rates after testis-sparing surgery; no adjuvant therapy option can be regarded as a standard of care. Patients with risk factors should undergo staging investigations. Those with metastatic disease have poor prognoses, and metastasectomy may be offered in selected cases.
Keyphrases
- risk factors
- squamous cell carcinoma
- single cell
- small cell lung cancer
- end stage renal disease
- cell therapy
- minimally invasive
- healthcare
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- palliative care
- prognostic factors
- type diabetes
- stem cells
- coronary artery bypass
- quality improvement
- metabolic syndrome
- acute coronary syndrome
- atrial fibrillation
- health insurance